泛素-蛋白酶体途径与恶性肿瘤关系的研究进展  

Advances in research on relation of ubiquitin-proteasome pathway to malignancy

作　　者：谢建军[1] 胡亚美[2] 吕有勇[3] 

机构地区：[1]解放军第304医院儿科,北京100037 [2]首都医科大学附属北京儿童医院,北京100045 [3]北京大学临床肿瘤学院,北京100037

出　　处：《中国癌症杂志》2002年第1期74-76,96,共4页China Oncology

摘　　要：泛素 蛋白酶体途径是调节多种细胞生物学过程的重要机制 ,也是恶性肿瘤相关调节异常的潜在靶点 ;这种途径通过其特殊的蛋白酶体裂解活性 ,可上调或下调某些抑癌基因、转录因子和细胞周期素等的表达以及改变MHC Ⅰ限制性抗原肽的生成 ,从而参与恶性肿瘤的发生和发展。Ubiquitin-proteasome pathway is an important mechanism regulating many processes of cellular biology,and also a potential target for abnormal regulation associated with malignancy. This pathway may up-regulate or down-regulate the expression of some tumor-inhibitory genes, transcriptional factors and cyclins,and alter the generation of MHC-I-restricting antigen peptides through the activity of specific proteasome, and consequently,participates in the genesis and progression of malignancy.

关 键 词：泛素 蛋白酶体 恶性肿瘤 相关关系 

分 类 号：R730.2[医药卫生—肿瘤]